中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (11): 811-815.doi: 10.12144/zgmfskin202511811

• 临床研究 • 上一篇    下一篇

阿布昔替尼快速改善慢性光化性皮炎三例并文献复习

童泽群1,2,3,曾雪婷1,2,3,黄辅晨1,2,3,纪超1,2,3   

  1. 1福建医科大学附属第一医院皮肤科，福建福州，350000;2福建医科大学附属第一医院奥体院区皮肤科，福建福州，350007；3皮肤肿瘤福建高州学校重点实验室，福建福州，350122
  • 出版日期:2025-11-15 发布日期:2025-11-11

Rapid improvement of chronic actinic dermatitis with abrocitinib: three cases report and literature review

TONG Zequn1,2,3, ZENG Xueting1,2,3, HUNAG Fuchen1,2,3, JI Chao1,2,3   

  1. 1 Department of Dermatology, the First Affiliated Hospital of Fujian Medical University, Fuzhou 350000, China; 2 Department of Dermatology, Aoti Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou 350007, China; 3 Key Laboratory of Skin Cancer of Fujian Higher Education Institutions, Fujian Medical University, Fuzhou 350122, China
  • Online:2025-11-15 Published:2025-11-11

PDF (PC)

33

摘要： 慢性光化性皮炎传统治疗包括外用糖皮质激素、钙凋磷酸酶抑制剂，严重者可选择口服羟氯喹、糖皮质激素、免疫抑制剂等系统治疗，但由于治疗效果欠佳，常需要患者进行长期用药，因此对患者产生较多不良反应。近年来，多个案例报道Janus激酶（Janus kinase, JAK）抑制剂对重度慢性光化性皮炎具有显著疗效，本项研究报道阿布昔替尼治疗慢性光化性皮炎3例，其中2例患者用药2周即实现皮损显著改善，1例4周完全缓解，未出现感染相关不良反应。本文中的两例患者分别采用50 mg/d减量方案随访6个月及3个月，病情持续缓解。此外本文归纳总结了国内外JAK抑制剂治疗慢性光化性皮炎的共16例病例，以期为临床提供有价值的诊疗参考和实践依据。

关键词: JAK抑制剂, 阿布昔替尼, 慢性光化性皮炎, 快速改善

Abstract: Traditional treatments for chronic actinic dermatitis (CAD) include topical glucocorticoids, calcineurin inhibitors; for severe cases, systemic treatments such as oral hydroxychloroquine, corticosteroids, and immunosuppressants are optional. However, due to suboptimal therapeutic outcomes, patients often require long-term medication, leading to numerous adverse effects. In recent years, Janus kinase (JAK) inhibitors have demonstrated significant efficacy in refractory CAD. We administered abrocitinib to three patients with chronic actinic dermatitis, two of whom showed marked improvement within two weeks, and one achieved complete remission after four weeks, with no infection-related adverse events observed. Two of the patients followed a tapering regimen of 50 mg/day and maintained remission during follow-up periods of six and three months, respectively. Furthermore, we summarized a total of 16 cases of JAK inhibitor treatment for CAD, aiming to provide valuable clinical references and practical guidance.

Key words: JAK inhibitors, abrocitinib, chronic actinic dermatitis, rapid improvement